CD274 and neoplasm: In our study, the low-risk group had a higher expression of PD-L1 in the tumor tissues than in the high-risk group, indicating a better efficacy of PD-L1 blockade, suggesting that the high-risk group could not benefit from PD-L1 blockade and tended to be immunotherapy-resistant.